An update on the compound challenge: 57825-30-6

From this literature《Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design》,we know some information about this compound(57825-30-6)SDS of cas: 57825-30-6, but this is not all information, there are many literatures related to this compound(57825-30-6).

Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 57825-30-6, is researched, Molecular C9H11Br, about Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design, the main research direction is S1P1 agonist oxazole triazole preparation pharmacophore modeling structure activity; Immunomodulator; Lymphocyte; Pharmacophore; Prodrug; S1P(1) agonist.SDS of cas: 57825-30-6.

We have discovered a series of triazole/oxazole-containing 2-substituted 2-aminopropane-1,3-diol derivatives as potent and selective S1P1 agonists (prodrugs) based on pharmacophore-guided rational design. Most compounds showed high affinity and selectivity for S1P1 receptor. Compounds 19b, 19d and 19p displayed clear dose responsiveness in the lymphocyte reduction model when administered orally at doses of 0.3, 1.0, 3.0 mg/kg with reduced effect on heart rate. These three compounds were also identified to have favorable pharmacokinetic properties.

From this literature《Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design》,we know some information about this compound(57825-30-6)SDS of cas: 57825-30-6, but this is not all information, there are many literatures related to this compound(57825-30-6).

Reference:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider